Skip to content
Wednesday, August 26, 2026
Women's Health Trial Tracker — 2010
| Record | Record Date | Vuga Group | Change Status | Recency Days | Public Significance Score |
|---|
| Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers | 01/20/2010 | INTERVENTIONAL | unchanged | 6,062.85 | 0 |
|---|
| Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4) | 02/08/2010 | INTERVENTIONAL | unchanged | 6,043.85 | 0 |
|---|
| Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | 02/12/2010 | INTERVENTIONAL | unchanged | 6,039.85 | 0 |
|---|
| Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | 03/05/2010 | INTERVENTIONAL | unchanged | 6,018.85 | 0 |
|---|
| Extending the National Health Service (NHS) Breast Screening Age Range | 03/05/2010 | INTERVENTIONAL | unchanged | 6,018.85 | 0 |
|---|
| Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | 03/05/2010 | INTERVENTIONAL | unchanged | 6,018.85 | 0 |
|---|
| Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer | 03/26/2010 | INTERVENTIONAL | unchanged | 5,997.85 | 0 |
|---|
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | 05/05/2010 | INTERVENTIONAL | unchanged | 5,957.85 | 0 |
|---|
| Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life | 05/31/2010 | OBSERVATIONAL | unchanged | 5,931.85 | 0 |
|---|
| Excision Followed by Radiofrequency Ablation for Breast Cancer | 06/29/2010 | INTERVENTIONAL | unchanged | 5,902.85 | 0 |
|---|
| Teriparatide (PTH) and Bone Strength in Postmenopausal Women | 07/01/2010 | OBSERVATIONAL | unchanged | 5,900.85 | 0 |
|---|
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | 07/22/2010 | INTERVENTIONAL | unchanged | 5,879.85 | 0 |
|---|
| Predictive Assays In Cervix Cancer | 08/13/2010 | INTERVENTIONAL | unchanged | 5,857.85 | 0 |
|---|
| Rehabilitation of Cognitive Changes in Breast Cancer Survivors | 08/16/2010 | INTERVENTIONAL | unchanged | 5,854.85 | 0 |
|---|
| Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors | 09/09/2010 | INTERVENTIONAL | unchanged | 5,830.85 | 0 |
|---|
| Relaxation for Women With Breast Cancer Undergoing Radiotherapy | 09/16/2010 | INTERVENTIONAL | unchanged | 5,823.85 | 0 |
|---|
| Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer | 09/16/2010 | INTERVENTIONAL | unchanged | 5,823.85 | 0 |
|---|
| Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | 10/29/2010 | INTERVENTIONAL | unchanged | 5,780.85 | 0 |
|---|
| Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | 11/19/2010 | INTERVENTIONAL | unchanged | 5,759.85 | 0 |
|---|
| Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | 11/22/2010 | INTERVENTIONAL | unchanged | 5,756.85 | 0 |
|---|
| National Pregnancy Registry for Psychiatric Medications | 11/23/2010 | OBSERVATIONAL | unchanged | 5,755.85 | 0 |
|---|
| Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer | 11/24/2010 | INTERVENTIONAL | unchanged | 5,754.85 | 0 |
|---|
| Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer | 12/24/2010 | INTERVENTIONAL | unchanged | 5,724.85 | 0 |
|---|